Neon Therapeutics bags a $70M round for early-stage neoantigen research
Neoantigens emerged as one of the hot new trends in biotech R&D a little more than a year ago. After a slate of cancer vaccines had struggled and failed in the clinic, the idea that you could fashion a vaccine directly targeting an individual patient’s tumors became fashionable in certain segments of the venture community. And a group of investors has joined hands to fund the next stage of clinical development at Neon Therapeutics with a hefty $70 million B round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.